🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to researchers.

A Global Challenge

Gonorrhoea infections are on the rise around the world, with figures suggesting in excess of 82 million new cases each year. Notably increased rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the reality of growing infection rates, the spread of superbugs and the highly restricted available drugs presently on offer.”

Medical experts are deeply concerned about the rise in drug-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Gain Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts hope that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This treatment, which is also used to treat urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This authorization signifies a huge turning point in the therapy of superbug gonorrhoea, which previously has been outpacing medical innovation.”

Testing Outcomes and Global Access

As per findings released by a major medical journal, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the existing first-line therapy, which uses two antibiotics. The trial enrolled over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the authority to make available and distribute the drug in many low-income and middle-income countries.

Doctors directly involved have voiced positive views. The availability of a single-dose, oral treatment such as this is described as a "critical tool" for gonorrhoea control. This is considered essential to reduce the burden of the illness for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.